Vor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder ...

Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

Biologics revolutionize generalized myasthenia gravis care with fast-acting, patient-friendly therapies and a robust global pipeline redefining outcomes. The gMG treatment era is shifting rapidly-from ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 19, 2025 /EINPresswire.com/ -- The market for Paroxysmal Nocturnal Hemoglobinuria PNH and Atypical Hemolytic Uremic Syndrome aHUS has seen remarkable ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug to make its mark. | In initial results from a phase 3 trial, Ultomiris ...

Ultomiris (ravulizumab-cwvz) is a prescription drug that treats certain rare inflammatory conditions in some people. Learn about dosage, side effects, and more.

Ultomiris is a prescription drug used to treat myasthenia gravis. Learn how the drug works, who receives it, and more.

The Business Research Company Ultomiris Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 <b> The ultomiri ...

Ultomiris, which is used to treat certain rare diseases, can cause side effects. Learn about its more common, mild, and serious side effects and how to manage them.

Learn about cost and Ultomiris, financial and insurance assistance, ways to lower long-term costs, and more.

FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.